Literature DB >> 15943008

Subjective well-being under the neuroleptic treatment and its relevance for compliance.

D Naber1, A Karow, M Lambert.   

Abstract

OBJECTIVE: To review the concept of 'subjective well-being under neuroleptic treatment', its development and clinical relevance,particularly regarding compliance.
METHOD: The manuscript includes a review of the limited literature and recent open and controlled clinical trials.
RESULTS: The patients' perspective of antipsychotic treatment was largely neglected for a long time. Scientific interest in this field of strong clinical relevance started mainly with the development of atypical antipsychotics. Recent research indicates that subjective well-being (SW) is a major determinant of medication compliance in schizophrenia. There are several self-report instruments with sufficient internal consistency and good construct validity. Effects of antipsychotic treatment on psychopathology and SW are only partly related. Most patients strongly prefer the atypical over typical antipsychotics. The assessment of SW is helpful for selecting the optimal drug for the individual patient.
CONCLUSION: SW, under antipsychotic treatment, is a valid construct; its assessment provides an independent outcome variable, which is relevant to compliance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943008     DOI: 10.1111/j.1600-0447.2005.00542.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  17 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  Rationale and parameters for medication-free research in psychosis.

Authors:  Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2006-02-03       Impact factor: 9.306

3.  Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.

Authors:  Iglika Vassileva; Vihra Milanova; Turan Asan
Journal:  Community Ment Health J       Date:  2014-01-23

Review 4.  Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.

Authors:  Hanjing Emily Wu; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2015-06

5.  Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study.

Authors:  Seoyoung Kim; Elena Younhye Ock; Jun Soo Kwon; Euitae Kim
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

6.  Olanzapine compared to quetiapine in adolescents with a first psychotic episode.

Authors:  Celso Arango; Olalla Robles; Mara Parellada; David Fraguas; Ana Ruiz-Sancho; Oscar Medina; Arantzazu Zabala; Igor Bombín; Dolores Moreno
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-05       Impact factor: 4.785

Review 7.  Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.

Authors:  Christoph U Correll; Taishiro Kishimoto; John M Kane
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

8.  Attitudes to antipsychotic drugs and their side effects: a comparison between general practitioners and the general population.

Authors:  Josef Helbling; Vladeta Ajdacic-Gross; Christoph Lauber; Ruth Weyermann; Tom Burns; Wulf Rössler
Journal:  BMC Psychiatry       Date:  2006-10-18       Impact factor: 3.630

9.  Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial.

Authors:  Wai Tong Chien; Jolene H C Mui; Eric F C Cheung; Richard Gray
Journal:  Trials       Date:  2015-06-14       Impact factor: 2.279

10.  Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample.

Authors:  Liina Haring; René Mõttus; Peeter Jaanson; Raine Pilli; Kairi Mägi; Eduard Maron
Journal:  Ann Gen Psychiatry       Date:  2013-09-11       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.